A Phase 1B Study of AMG-232 in Combination With Decitabine in Acute Myeloid Leukemia

Trial Profile

A Phase 1B Study of AMG-232 in Combination With Decitabine in Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2018

At a glance

  • Drugs AMG 232 (Primary) ; Decitabine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Apr 2018 Status changed from suspended to recruiting.
    • 07 Feb 2018 Status changed from recruiting to suspended, as protocol amendment is required.
    • 04 Jan 2018 Planned number of patients changed from 40 to 58.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top